MCID: ART008
MIFTS: 42

Arteriosclerosis Obliterans malady

Categories: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

Aliases & Descriptions for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 12 52 42 14 69
Arteriosclerosis Obliterans [ambiguous] 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5160
MeSH 42 D001162
SNOMED-CT 64 361133006 60625000
UMLS 69 C0003851

Summaries for Arteriosclerosis Obliterans

MalaCards based summary : Arteriosclerosis Obliterans, also known as arteriosclerosis obliterans [ambiguous], is related to myocardial infarction and arteriosclerosis. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways/superpathways are HTLV-I infection and Dilated cardiomyopathy. The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include heart, smooth muscle and bone, and related phenotypes are cardiovascular system and cellular

Wikipedia : 71 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

Related Diseases for Arteriosclerosis Obliterans

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
id Related Disease Score Top Affiliating Genes
1 myocardial infarction 29.6 ADIPOQ ICAM1 IL6 SELP VCAM1
2 arteriosclerosis 10.9
3 cryptosporidiosis 10.2 IL6 SELP
4 latent syphilis 10.2 ICAM1 IL6
5 neuroaxonal dystrophy 10.2 ICAM1 IL6
6 macrodactyly of the foot 10.2 ICAM1 VCAM1
7 periosteal chondrosarcoma 10.2 ICAM1 VCAM1
8 right ventricle hypoplasia 10.2 ICAM1 VCAM1
9 phlegmonous dacryocystitis 10.1 ICAM1 VCAM1
10 aneurysm 10.1
11 ovarian clear cell malignant adenofibroma 10.1 ICAM1 VCAM1
12 dislocation of ear ossicle 10.1 ICAM1 VCAM1
13 congenital chloride diarrhea 10.1 IL6 SELP VCAM1
14 heart disease 10.1
15 lymphedema 10.1 ICAM1 VCAM1
16 ependymoblastoma 10.1 ICAM1 SELP VCAM1
17 xerophthalmia 10.1 ICAM1 SELP VCAM1
18 conduct disorder 10.1 ICAM1 IL6
19 gait apraxia 10.1 ADIPOQ ICAM1 IL6
20 intra-abdominal lymph node mast cell malignancy 10.1 ICAM1 SELP VCAM1
21 erb-duchenne and dejerine-klumpke palsies 10.1 ICAM1 IL6 VCAM1
22 lymph node disease 10.1 ICAM1 ITGA4
23 multilocular clear cell renal cell carcinoma 10.1 ICAM1 IL6
24 pemphigus vulgaris, familial 10.1 ICAM1 IL6 VCAM1
25 ischemic optic neuropathy 10.1 HTR2A IL6 SELP
26 synovium cancer 10.1 ICAM1 IL6 VCAM1
27 pigmentation disease 10.1 ICAM1 IL6 VCAM1
28 ischemia 10.1
29 aortic aneurysm 10.1
30 degenerative disc disease 10.0 HGF IL6
31 mucinoses 10.0 ADIPOQ IL6 SELP VCAM1
32 artery disease 10.0
33 hypopyon ulcer 10.0 ICAM1 ITGA4 VCAM1
34 diabetes mellitus, insulin-dependent, 20 10.0 ADIPOQ IL6 SELP VCAM1
35 cervix small cell carcinoma 10.0 ICAM1 IL6 SELP VCAM1
36 pyriform sinus cancer 9.9 ICAM1 IL6
37 autoimmune-related retinopathy and optic neuropathy 9.9 ADIPOQ ICAM1 IL6 VCAM1
38 pericarditis 9.9 ADIPOQ SELP VCAM1
39 immunodeficiency due to defect in mapbp-interacting protein 9.9 ICAM1 IL6 SELP VCAM1
40 diabetic encephalopathy 9.9 ADIPOQ HTR2A ICAM1 IL6
41 atherosclerosis 9.9
42 intermittent claudication 9.9
43 ischemic heart disease 9.9
44 peripheral artery disease 9.9
45 cerebritis 9.9
46 abdominal aortic aneurysm 9.9
47 maturity-onset diabetes of the young 6 9.9 ADIPOQ IL6 SELP VCAM1
48 epidermolysis bullosa simplex, sutosomal recessive 2 9.9 HGF ICAM1 VCAM1
49 lymphoid leukemia 9.9 ADIPOQ HGF IL6
50 perrault syndrome 9.9 ICAM1 ITGA4 SELP VCAM1

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to Arteriosclerosis Obliterans

Symptoms & Phenotypes for Arteriosclerosis Obliterans

MGI Mouse Phenotypes related to Arteriosclerosis Obliterans:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 ITGA4 SELP VCAM1 ADIPOQ HGF ICAM1
2 cellular MP:0005384 9.5 ADIPOQ HGF ICAM1 IL6 ITGA4 SELP
3 hematopoietic system MP:0005397 9.17 ADIPOQ HGF ICAM1 IL6 ITGA4 SELP

Drugs & Therapeutics for Arteriosclerosis Obliterans

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Cilostazol Approved Phase 4 73963-72-1 2754
3
Probucol Approved Phase 4 23288-49-5 4912
4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Remifentanil Approved Phase 4 132875-61-7 60815
7
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
8 Analgesics Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Anti-Asthmatic Agents Phase 4
11 Anti-Inflammatory Agents Phase 4
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4
13 Antipyretics Phase 4
14 Antirheumatic Agents Phase 4
15 Autonomic Agents Phase 4
16 Bronchodilator Agents Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 Fibrinolytic Agents Phase 4
19 Neuroprotective Agents Phase 4
20 Peripheral Nervous System Agents Phase 4
21 Phosphodiesterase 3 Inhibitors Phase 4
22 Phosphodiesterase Inhibitors Phase 4
23 Platelet Aggregation Inhibitors Phase 4,Phase 2
24 Protective Agents Phase 4
25 Respiratory System Agents Phase 4
26 Vasodilator Agents Phase 4,Phase 2
27 Anticholesteremic Agents Phase 4
28 Antimetabolites Phase 4
29 Antioxidants Phase 4
30 Hypolipidemic Agents Phase 4
31 Lipid Regulating Agents Phase 4
32
Angiotensin II Phase 4 68521-88-0, 11128-99-7 65143 172198
33 Angiotensin II Type 1 Receptor Blockers Phase 4
34 Angiotensin Receptor Antagonists Phase 4
35 Angiotensin-Converting Enzyme Inhibitors Phase 4
36 Angiotensinogen Phase 4
37 Antihypertensive Agents Phase 4
38 diuretics Phase 4
39 Natriuretic Agents Phase 4
40 Sodium Chloride Symporter Inhibitors Phase 4
41 Analgesics, Opioid Phase 4
42 Anesthetics Phase 4,Phase 1,Phase 2
43 Anesthetics, General Phase 4
44 Anesthetics, Inhalation Phase 4
45 Anesthetics, Intravenous Phase 4
46 Central Nervous System Depressants Phase 4
47 Hypnotics and Sedatives Phase 4
48 Narcotics Phase 4
49
Alprostadil Approved, Investigational Phase 2 745-65-3 149351
50 Anticoagulants Phase 2

Interventional clinical trials:

(show all 17)
id Name Status NCT ID Phase
1 Sufficient Treatment of Peripheral Intervention by Cilostazol Unknown status NCT00912756 Phase 4
2 Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4
3 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4
4 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4
5 Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Recruiting NCT02107170 Phase 4
6 TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation Unknown status NCT00145262 Phase 2
7 Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia Unknown status NCT01446055 Phase 1, Phase 2
8 Autologous Bone Marrow For Lower Extremity Ischemia Treating Completed NCT00753025 Phase 2
9 A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans Recruiting NCT02877173 Phase 2
10 Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia Enrolling by invitation NCT02864654 Phase 1, Phase 2
11 Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Not yet recruiting NCT02501018 Phase 2
12 Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages Completed NCT00712946
13 HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F) Completed NCT01518205
14 ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease Completed NCT01064206
15 Long Superficial Femoral Artery Stenting With SuperA Interwoven Nitinol Stents Recruiting NCT03020290
16 Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia Recruiting NCT02089828
17 Arterial Calcification in the Diabetes Active, not recruiting NCT02431234

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

Anatomical Context for Arteriosclerosis Obliterans

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

39
Heart, Smooth Muscle, Bone, Skin, Bone Marrow, T Cells, Endothelial

Publications for Arteriosclerosis Obliterans

Articles related to Arteriosclerosis Obliterans:

(show top 50) (show all 241)
id Title Authors Year
1
Emerging Novel Biomarkers for Arteriosclerosis Obliterans. ( 26632166 )
2016
2
Baseline Characterization of Japanese Peripheral Arterial Disease Patientsa88- Analysis of Surveillance of Cardiovascular Events in Antiplatelet-Treated Arteriosclerosis Obliterans Patients in Japan (SEASON). ( 26841805 )
2016
3
A Rare Complication of Spinal Cord Ischemia Following Endovascular Aneurysm Repair of an Infrarenal Abdominal Aortic Aneurysm with Arteriosclerosis Obliterans: Report of a Case. ( 27738476 )
2016
4
Investigating the Role of the Posttranscriptional Gene Regulator MiR-24- 3p in the Proliferation, Migration and Apoptosis of Human Arterial Smooth Muscle Cells in Arteriosclerosis Obliterans. ( 26159387 )
2015
5
MicroRNA-133a in the Development of Arteriosclerosis Obliterans. ( 25740337 )
2015
6
Logistic Regression Analysis of Depression in Arteriosclerosis Obliterans Patients and Its Risk Factors. ( 26564507 )
2015
7
Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study. ( 25959199 )
2015
8
Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. ( 26370316 )
2015
9
Involvement of MicroRNA-133a in the Development of Arteriosclerosis Obliterans of the Lower Extremities via RhoA Targeting. ( 25445891 )
2014
10
MiR-142-3p attenuates the migration of CD4a8_ T cells through regulating actin cytoskeleton via RAC1 and ROCK2 in arteriosclerosis obliterans. ( 24743945 )
2014
11
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( 23364237 )
2013
12
Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. ( 23749750 )
2013
13
Relationship between Arteriosclerosis Obliterans and the Ratio of Serum Eicosapentaenoic Acid to Arachidonic Acid. ( 23364231 )
2013
14
A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol. ( 23097651 )
2012
15
Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study. ( 23065872 )
2012
16
Retrograde perfusion of the hind leg in diabetic patients suffering from arteriosclerosis obliterans: theoretical considerations of oxygen supply and lymphatic flow based on rat models. ( 22259111 )
2012
17
MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. ( 21817107 )
2011
18
Characteristics of revascularization treatment for arteriosclerosis obliterans in patients with and without hemodialysis. ( 20938099 )
2010
19
The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. ( 20357749 )
2010
20
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON). ( 20966606 )
2010
21
Current status of the medical expenses for the treatment of arteriosclerosis obliterans in Japan. ( 20357751 )
2010
22
[Evaluation of proinflammatory cytokines in chronic lower limb ischaemia diabetic macroangiopathy and arteriosclerosis obliterans]. ( 20120706 )
2009
23
Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans. ( 19225945 )
2009
24
Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans. ( 18175063 )
2008
25
Detecting vulnerable plaque of arteriosclerosis obliterans by multidetector-row computed tomography--comparing with VH (virtual histology)-intravascular ultrasound. ( 17512620 )
2008
26
Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. ( 18270875 )
2008
27
Changes in the activities of daily living (ADL) in relation to the level of amputation of patients undergoing lower extremity amputation for arteriosclerosis obliterans (ASO). ( 18724029 )
2008
28
Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. ( 18375400 )
2008
29
Serum levels of S-glutathionylated proteins as a risk-marker for arteriosclerosis obliterans. ( 17186986 )
2007
30
Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. ( 18064333 )
2007
31
Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. ( 17126824 )
2007
32
Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. ( 17652880 )
2007
33
Intractable wounds caused by arteriosclerosis obliterans with end-stage renal disease treated by aggressive debridement and epidermal grafting. ( 17637445 )
2007
34
Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms. ( 17610290 )
2007
35
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans. ( 17249520 )
2006
36
Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans. ( 16865304 )
2006
37
Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. ( 16763534 )
2006
38
Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. ( 15877296 )
2005
39
Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. ( 15488869 )
2004
40
Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. ( 15564705 )
2004
41
Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. ( 14983238 )
2004
42
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. ( 15203718 )
2004
43
The effect of Liple on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. ( 15765038 )
2004
44
Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease. ( 15224807 )
2004
45
Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. ( 15080020 )
2004
46
Three cases of ischemic ulcer due to arteriosclerosis obliterans responding to basic fibroblast growth factor spray. ( 15372302 )
2004
47
Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ( 12918586 )
2003
48
Percutaneous transluminal angioplasty against arteriosclerosis obliterans in dialysis patients. ( 12579341 )
2003
49
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ( 14583180 )
2003
50
Peripheral macrohemodynamics in patients with lower limb arteriosclerosis obliterans and type II diabetes mellitus. ( 12811388 )
2003

Variations for Arteriosclerosis Obliterans

Expression for Arteriosclerosis Obliterans

Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for Arteriosclerosis Obliterans

Pathways related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1 12.18 ICAM1 IL6 VCAM1
2
Show member pathways
12 IL6 ITGA4 TPM1
3
Show member pathways
11.92 ICAM1 ITGA4 VCAM1
4 11.86 ICAM1 ITGA4 VCAM1
5 11.85 HGF IL6 VCAM1
6 11.78 ICAM1 IL6 SELP
7 11.73 ICAM1 ITGA4 VCAM1
8 11.72 ICAM1 ITGA4 SELP VCAM1
9 11.7 ICAM1 IL6 VCAM1
10 11.65 ICAM1 IL6 VCAM1
11 11.62 ADIPOQ IL6 VCAM1
12 11.51 HGF ICAM1 IL6 VCAM1
13
Show member pathways
11.41 ICAM1 IL6 VCAM1
14 11.26 ICAM1 IL6 SELP
15
Show member pathways
11.24 ITGA4 VCAM1
16 11.19 ICAM1 ITGA4 VCAM1
17 11.1 ICAM1 IL6 ITGA4 VCAM1
18 11.04 ICAM1 IL6 VCAM1
19 10.92 ADIPOQ IL6
20 10.74 ICAM1 VCAM1
21 10.71 HGF ICAM1 IL6 SELP VCAM1

GO Terms for Arteriosclerosis Obliterans

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.46 ADIPOQ ICAM1 ITGA4 VCAM1
2 extracellular space GO:0005615 9.43 ADIPOQ HGF ICAM1 IL6 SELP VCAM1
3 external side of plasma membrane GO:0009897 8.92 ICAM1 IL6 SELP VCAM1

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.93 ICAM1 ITGA4 SELP VCAM1
2 leukocyte migration GO:0050900 9.8 ICAM1 ITGA4 SELP
3 extracellular matrix organization GO:0030198 9.79 ICAM1 ITGA4 VCAM1
4 regulation of immune response GO:0050776 9.77 ICAM1 ITGA4 VCAM1
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.77 HTR2A ICAM1 IL6
6 aging GO:0007568 9.76 HTR2A IL6 VCAM1
7 response to hypoxia GO:0001666 9.75 ADIPOQ ICAM1 VCAM1
8 regulation of cell shape GO:0008360 9.73 ICAM1 IL6 TPM1
9 response to drug GO:0042493 9.71 ADIPOQ HTR2A ICAM1 IL6
10 response to ethanol GO:0045471 9.67 ADIPOQ ICAM1 VCAM1
11 negative regulation of fat cell differentiation GO:0045599 9.65 ADIPOQ IL6
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.65 ICAM1 IL6
13 cellular response to tumor necrosis factor GO:0071356 9.65 ICAM1 IL6 VCAM1
14 response to amino acid GO:0043200 9.64 ICAM1 IL6
15 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.64 HGF ICAM1
16 cellular response to dexamethasone stimulus GO:0071549 9.63 ICAM1 IL6
17 positive regulation of vasoconstriction GO:0045907 9.62 HTR2A ICAM1
18 response to lipopolysaccharide GO:0032496 9.62 ICAM1 IL6 SELP VCAM1
19 cellular response to cytokine stimulus GO:0071345 9.61 IL6 ITGA4
20 calcium-mediated signaling using intracellular calcium source GO:0035584 9.57 SELP VCAM1
21 cellular response to hepatocyte growth factor stimulus GO:0035729 9.55 HGF IL6
22 negative regulation of gluconeogenesis GO:0045721 9.54 ADIPOQ IL6
23 acute inflammatory response GO:0002526 9.52 IL6 VCAM1
24 positive regulation of leukocyte migration GO:0002687 9.51 ITGA4 SELP
25 cellular response to nutrient levels GO:0031669 9.46 ICAM1 IL6
26 negative regulation of hormone secretion GO:0046888 9.43 ADIPOQ IL6
27 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.43 ICAM1 SELP VCAM1
28 membrane to membrane docking GO:0022614 9.37 ICAM1 VCAM1
29 leukocyte tethering or rolling GO:0050901 9.33 ITGA4 SELP VCAM1
30 leukocyte cell-cell adhesion GO:0007159 9.26 ICAM1 ITGA4 SELP VCAM1
31 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.02 ADIPOQ HGF HTR2A ICAM1 IL6

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sialic acid binding GO:0033691 8.62 ADIPOQ SELP

Sources for Arteriosclerosis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....